Senior Manager, Statistical Programming
Alnylam Pharmaceuticals
Summary
The Senior Manager Statistical Programming will provide leadership and expert-level hands-on support to programmers. The senior manager may also guide the professional development of statistical programmers within the company. The position requires a broad, comprehensive and detailed understanding of statistical programming languages and software, industry best practices, clinical trial databases, regulatory filings, and pharmaceutical drug development.
Job description
Summary of Key Responsibilities
- Oversees the work of internal statistical programmers. Provides technical guidance and mentoring
- Provides timely support to study teams on all programming matters according to product strategies
- Performs, plans and coordinates project work to ensure timely, quality delivery across multiple projects
- Contributes to strategic initiatives to improve departmental processes and scalability
- May function as lead programmer to produce or validate tables, listings, figures and analysis datasets
- Writes specifications to describe programming needs
- Creates and validates global macros or systems that streamline repetitive operations to increase programming efficiency
- Keeps abreast of current and new statistical programming techniques and other applicable technical advancements while assisting in their implementation
- Provides input into, or leads general standardization efforts (e.g., CRFs, query checks, standard statistical programs, data presentations)
- Assists in developing programming processes consistent with industry best practices
- Reviews DMP, eCRF specs, and other clinical data management documents
- Reviews statistical analysis plans and other related documents
- Partners with or oversee CROs or Programming vendors to perform any of the above tasks
- Other duties as assigned
Qualifications
- At least 8 years' industry (Pharmaceutical, Biotech, CRO) SAS programming experience or equivalent; At least 2 years management experience
- Knowledge of clinical trials and experience in using SAS to report the results of clinical trials and/or integrated analysis for submission
- Experience in constructing technical programming specifications and producing validated SAS programs
- Strong experience in working with CDISC standards, including SDTM, and ADaM and define documentation
- Excellent knowledge of applied statistical methodologies
- Excellent knowledge of SAS Macro, SAS/SQL, SAS/GRAPH, and SAS/STAT
- Good communications and organizational skills required
- Bachelor's Degree required, Master's Degree Preferred
Requirements
- At least 8 years' industry (Pharmaceutical, Biotech, CRO) SAS programming experience or equivalent
- At least 2 years management experience
- Knowledge of clinical trials and experience in using SAS to report the results of clinical trials and/or integrated analysis for submission
- Experience in constructing technical programming specifications and producing validated SAS programs
- Strong experience in working with CDISC standards, including SDTM, and ADaM and define documentation
- Excellent knowledge of applied statistical methodologies
- Excellent knowledge of SAS Macro, SAS/SQL, SAS/GRAPH, and SAS/STAT
- Good communications and organizational skills required
- Bachelor's Degree required
- Master's Degree Preferred
Benefits
- Medical, Dental & Vision
- Life & Disability Insurance
- Lifestyle Reimbursement Program
- Flexible Spending Accounts
- Health Savings Accounts
- 401(k) Matching
- Paid Time Off
- Wellness Days
- Holidays
- Company-wide Recharge Breaks
- Family Resources
- Leave
Company overview
Alnylam Pharmaceuticals is a pioneering American biopharmaceutical company and the global leader in RNA interference (RNAi) therapeutics. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has revolutionized the field of genetic medicine by developing innovative treatments that 'silence' disease-causing genes. The company achieved a historic milestone in 2018 with the approval of Onpattro (patisiran), the world's first RNAi therapeutic, which treats hereditary transthyretin-mediated amyloidosis. Since then, Alnylam has successfully commercialized five additional RNAi medicines targeting rare genetic disorders including acute hepatic porphyria, primary hyperoxaluria type 1, and transthyretin amyloidosis. With over 2,100 employees worldwide, Alnylam maintains a robust pipeline of investigational therapies across genetic medicines, cardiometabolic diseases, and hepatic infectious diseases. The company's groundbreaking work has established RNAi as a clinically validated therapeutic platform, earning recognition as one of the most innovative biopharmaceutical companies and consistently ranking as a top employer in the life sciences industry.